Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as…
Disclosure of Share Capital and Voting Rights Outstandingas of July 31, 2025(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)Paris, France (September 1, 2025 - 6:00 pm)– As of July 31, 2025, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as...
Nasdaq GlobeNewswire
01/09/2025
Oxurion confirms progress in negotiations related to its treasury…
Leuven, BELGIUM – September 1, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that negotiations with Atlas Special Opportunities regarding the financing agreement are progressing constructively. The company expects to close the transaction before September 25, 2025…
Actusnews Wire
01/09/2025
Oxurion bevestigt de vooruitgang van de onderhandelingen over haar strategie…
Leuven, BELGIË – 1 september 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, kondigt aan dat de onderhandelingen met Atlas Special Opportunities over de financieringsovereenkomst constructief verlopen. De vennootschap verwacht de transactie vóór 25 september 2025 af te ronden…
Actusnews Wire
01/09/2025
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II…
Leuven, BELGIUM – September 1, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on August 28, 2025, from Atlas Special…
Actusnews Wire
01/09/2025
Idorsia furthers the science of sleep and insomnia at World Sleep 2025
Allschwil, Switzerland – September 1, 2025Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World Sleep 2025, a global scientific congress bringing the best of sleep medicine and research, in Singapore from September 5-10, 2025.Idorsia’s scientific poster presentations at World Sleep 2025: Real-world data assessment of abuse potential of insomnia therapiesA study to examine the real-world...
Nasdaq GlobeNewswire
01/09/2025
Flexible Endoscopes Market worth US$3.07 billion by 2030 with 5.1 % CAGR |…
Browse in-depth TOC on "Flexible Endoscopes Market" Browse in-depth TOC on "Flexible Endoscopes Market" 443 - Tables 48 - Figures 329 - Pages By type,the flexible endoscopes market is segmented into upper gastrointestinal endoscopes, colonoscopes, broncoscopes, sigmoidoscopes, laryngoscopes, pharyngoscopes, duodenoscopes, nasopharyngoscopes, rhinoscopes, and other types. The upper gastrointestinal endoscopes segment accounted for the largest market share in 2024. The...
PR Newswire
01/09/2025
Digital Pathology Market to Grow at a CAGR of 7.8% from 2025 to 2032 | SkyQuest…
Get Free Sample Report Copy: https://www.skyquestt.com/sample-request/digital-pathology-market Get Free Sample Report Copy:https://www.skyquestt.com/sample-request/digital-pathology-market Digital Pathology Market Key Growth Drivers The digital pathology market has experienced significant growth owing to expanding healthcare access needs, especially in rural and underserved areas, telepathology is gaining momentum. Digital pathology allows remote sharing of slides for expert...
PR Newswire
01/09/2025
Contract Research Organization (CRO) Services Market worth $125.95 billion in…
Browse in-depth TOC on "Contract Research Organization Services Market" Browse in-depth TOC on "Contract Research Organization Services Market" 626- Tables 57 - Figures 400 - Pages By modality,the CRO services market is segmented into small molecules, biologics, medical devices, and biosimilars. The medical devices segment is projected to register the highest CAGR during the forecast period. The high growth rate of this segment is attributed to factors such as the high...
PR Newswire
01/09/2025
Immunoassay Market worth $47.7 billion by 2030 with 6.1% CAGR |…
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436 Browse in-depth TOC on "Immunoassay Market" 570 - Tables 65 - Figures 492- Pages By product,the immunoassay market, by product, is segmented into reagents & kits and analyzers. In 2024, the reagents and kits segment held the largest market share. This significant share is mainly due to the recurring...
PR Newswire
01/09/2025
Oslo University Hospital to conduct randomized phase 2 trial of ILB® in ALS…
The study is sponsored by Oslo University Hospital, funded by public research grants and is open to Norwegian residents only. Tikomed will supply ILB for both study phases as well as corresponding placebo for the RCT. The study is sponsored byOslo UniversityHospital, funded by public research grants and is open to Norwegian residents only. Tikomed will supply ILB for both study phases as well as corresponding placebo for the RCT. The study has received all required regulatory approvals...
PR Newswire
01/09/2025
KLEA HOLDING (ex VISIOMED GROUP) : Klea Holding repurchases and cancels PARK…
KLEA HOLDING (FR0013481835 – ALKLH), a group focused on the acquisition, development and digital transformation of businesses across multiple sectors, announces the repurchase and cancellation of 20,000,652 outstanding PARK warrants for a total amount of €462,885, broken down as follows: PARK warrants - Tranche 3: 16,233,767 warrants repurchased…
Actusnews Wire
01/09/2025
VICENZAORO SEPTEMBER 2025: THE GLOBAL JEWELLERY SUPPLY CHAIN IN VICENZA WITH IEG
The BtoB fair anticipates market and design trends with the world premiere of The Jewellery Trendbook 2027+ by IEG/Vicenzaoro's independent Trendvision Jewellery + Forecasting Observatory. The BtoB fair anticipates market and design trends with the world premiere ofThe Jewellery Trendbook 2027+by IEG/Vicenzaoro's independent Trendvision Jewellery + Forecasting Observatory. Also scheduled is the second annual edition ofVO Vintage(5–8 September), open to collectors and enthusiasts…
PR Newswire
01/09/2025
Data4Life announces the appointment of Dr. Ben Illigens as new CEO by the Hasso…
"Digital technologies and artificial intelligence are fundamentally transforming health research and care. They hold enormous promise but also raise important questions of ethics, equity, and bias. My goal is to strengthen Data4Life as a bridge between clinical research, technology, and practice, ensuring that innovations are implemented fairly, responsibly, and sustainably," said Dr. Ben Illigens. "Digital technologies and artificial intelligence are fundamentally transforming…
PR Newswire
01/09/2025
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute…
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking sessionExpanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DME) to be presented Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations...
Nasdaq GlobeNewswire
01/09/2025
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for…
This press release is not intended for UK and US media. HERNEXEOS ® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1 clinical trial 1 Zongertinib recently received Breakthrough Therapy Designation for the first-line treatment of advanced HER2-mutant NSCLC by the Center for Drug Evaluation (CDE)Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has been approved as monotherapy by China’s National...
Nasdaq GlobeNewswire
01/09/2025
AMI Pharm's AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in…
The Phase 2 study enrolled 96 participants and demonstrated strong results. At four weeks after the final treatment, 69.70% of participants in the 25 mg/mL treatment group achieved at least a one-grade improvement in both the Evaluator-Reported and Subject-Reported Submental Fat Rating Scales (ER-SMFRS and SR-SMFRS). This was a statistically significant improvement compared to the 22.58% response rate in the placebo group. The trial data also highlighted AYP-101's favorable safety and…
PR Newswire
01/09/2025
POLYTECH Health & Aesthetics Expands into Poland with Direct Operations
Surgeons and patients in Poland will now benefit from direct access to POLYTECH's differentiated product portfolio, including B-Lite®, the world's only lightweight breast implants, as well as the highly regarded MESMO® and Microthane® implants, renowned globally for their safety, quality and long-term outcomes. Surgeons and patients inPolandwill now benefit from direct access to POLYTECH's differentiated product portfolio, includingB-Lite®, the world's only lightweight breast implants,...
PR Newswire
01/09/2025
Ulike Sponsors Beauty Hub at IFA 2025, Raising the Bar for At-Home Skincare Tech
Ulike Sponsoring IFA's Beauty Hub Ulike Sponsoring IFA's Beauty Hub IFA will debut its first-ever Beauty Hub this year, with Ulike powering it. The Hub will celebrate its premiere as the highlight of theFitness & Digital Health AreainHall 17, showcasing smart beauty innovations in self-care. After making waves in the Asian and North American skincare market, the brand hasEuropeas its next key market. Ulike already holds partnerships with top department stores inEurope...
PR Newswire
01/09/2025
Berlin Heals Holding AG Successfully Raises Over 5Million USD Round for…
The implant consists of two electrodes connected to an implantable generator that provides constant direct microcurrent across the diseased heart. This constant DC current reduces inflammation and reverse remodels the heart, which has been shown in previous studies to improve cardiac function and reduce symptoms. The implant consists of two electrodes connected to an implantable generator that provides constant direct microcurrent across the diseased heart. This constant DC current reduces...
PR Newswire
01/09/2025
University medical center in Germany expands use of Sectra's solution with AI…
He continues: "Having already seen workflow improvements with Sectra's enterprise imaging solution, expanding our partnership was a natural next step. With all AI applications available in one place, through a single vendor, and already validated by Sectra—who also takes full responsibility for implementation and operation—made it far easier to move from curiosity to reality. This will remove much of the complexity and time investment for us, enabling us to benefit from AI from day…
PR Newswire
01/09/2025
CMEF 2025: Promoting Holistic and High-Quality Development of Medical and Health…
The fair will feature 28 themed zones spanning medical imaging, in vitro diagnostics, surgical robots, smart healthcare, and more—showcasing the full ecosystem from upstream R&D to end‑user applications. Focus areas include smart technology innovation, supply‑chain collaboration, international resource integration, precision medicine, and solutions for an aging population. The fair will feature 28 themed zones spanning medical imaging, in vitro diagnostics, surgical robots, smart…
PR Newswire
01/09/2025
Jenscare Announces 2025H1 Interim Results
LuX-Valve Series, TTVR system LuX-Valve Series, TTVR system Ken-Valve, TAVR (AR) system JensClip, TMVr system Financial Highlights: Great Profitability in Sales Activities View original content: https://www.prnewswire.co.uk/news-releases/jenscare-announces-2025h1-interim-results-302542557.html
PR Newswire
01/09/2025
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57%…
Compared with tirzepatide, Wegovy ®(semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment 1 Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy ®users compared with tirzepatide users in all treated people, regardless of any gaps in their treatment...
Nasdaq GlobeNewswire
31/08/2025
Novartis Leqvio® shows statistically significant and clinically meaningful early…
V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein cholesterol (LDL-C) goals early with reduced muscle pain 1 85% of patients on Leqvio plus individually optimized lipid-lowering therapy (LLT) achieved LDL-C targets within 90 days vs. 31% of patients on placebo plus LLT 1 Patients on Leqvio plus LLT were 43% less likely to experience muscle-related adverse events compared to those on placebo...
Nasdaq GlobeNewswire
30/08/2025
Altri Comunicati
